Over 1850 Total Lots Up For Auction at Six Locations - MA 04/30, NJ Cleansweep 05/02, TX 05/03, TX 05/06, NJ 05/08, WA 05/09

CEUS underutilization may pose greater risk than rare side effects associated with use, say experts

Press releases may be edited for formatting or style | September 11, 2023 Ultrasound
CHICAGO--(BUSINESS WIRE)--Contrast enhanced ultrasound (CEUS) is underutilized in the United States, and reduced access to this noninvasive diagnostic imaging tool may pose a greater risk to patients than rare side effects associated with use, according to doctors who spoke today at the 37th International Bubble Conference in Chicago.

The conference drew CEUS experts from North America, Europe, China and Brazil, and focused on advances in the use of “microbubble” ultrasound enhancing agents (UEAs) used routinely worldwide to diagnose heart and vascular disease, identify and characterize tumors, monitor chronic gastro-intestinal diseases, evaluate other serious medical conditions and monitor therapy. UEAs do not contain dye, create no known risk of kidney damage or deposit of contrast media in the brain, and do not expose patients or hospital staff to ionizing radiation.

“CEUS is among the safest of contrast media available,” according to Dr. Strom, an Assistant Professor of Medicine at Harvard Medical School and Director of the Echocardiography Laboratory at Beth Israel Deaconess Medical Center in Boston. He noted that UEAs present a rare risk of a severe allergic reaction in 1/15,000 patients. By comparison, iodinated contrast agents used for CT present a risk of life threatening reactions in 1/500 to 1/5,000 patients. In addition, cardiac angiography presents a risk of death in 1/1,000 patients, and SPECT or MUGA imaging presents a risk of fatal malignancies in 1/1,000-1/10,000 patients.

To reduce UEA risk even further, Dr. Strom said “dilution of the agent is key.” He noted that vendors are not allowed to recommend UEA dilution because government regulations prohibit them from providing information that is not expressly contained in product labels approved by the FDA.

Dr. Strom suggested that clinical applications specialists may, however, refer customers to new professional guidelines recently published in Echo Research and Practice: “CEUS cardiac exam protocols: International Contrast Ultrasound Society (ICUS) recommendations.” These guidelines address dilution and other evidence-based options for optimal UEA administration.

Dr. Strom also stressed the importance of preparedness for rare adverse events, and recommended staff training and assessment, detailed planning for a local response including who is responsible for specific tasks, having allergy kits available and stocked, tracking any issues and debriefing afterward. He also recommended posting a safety placard and having an emergency pager that is always covered.

You Must Be Logged In To Post A Comment